Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239088 | 1.00 | POLB (0.46) | POLBMAPTHPGDLMNAGAA | |
| SCHEMBL5493098 | 1.00 | POLB (0.46) | POLBMAPTHPGDLMNAGAA | |
| SCHEMBL2232374 | 0.84 | NFE2L2 (0.53) | POLBMAPTLMNAGAATSHR | |
| SCHEMBL3310563 | 0.84 | NFE2L2 (0.53) | POLBMAPTLMNAGAATSHR | |
| SCHEMBL2232370 | 0.84 | NFE2L2 (0.53) | POLBMAPTLMNAGAATSHR | |
| SCHEMBL933237 | 0.82 | MAPT (0.45) | MAPTHPGDLMNAGAATSHR | |
| SCHEMBL933235 | 0.82 | MAPT (0.45) | MAPTHPGDLMNAGAATSHR | |
| SCHEMBL629545 | 0.81 | ALDH1A1 (0.57) | MAPTHPGDLMNAGAACYP1A2 | |
| SCHEMBL629546 | 0.81 | ALDH1A1 (0.57) | MAPTHPGDLMNAGAACYP1A2 | |
| SCHEMBL2231488 | 0.81 | ALDH1A1 (0.60) | MAPTHPGDLMNAGAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171444-A1 | Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2014-06-19 | — | — | US | claimed |
| US-20140171444-A1 | Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2014-06-19 | — | — | US | disclosed |
| US-8664255-B2 | Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2014-03-04 | — | — | US | disclosed |
| WO-2011092505-A1 | S100 PROTEIN BINDING INTERACTION INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-08-04 | — | — | WO | disclosed |
| US-20100113477-A1 | Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof | TEXAS A&M UNIVERSITY SYSTEM, THE | 2010-05-06 | — | — | US | disclosed |
| WO-2010047774-A2 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS MALATE SYNTHASE, METHODS OF MARKING AND USES THEREOF | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20070225335-A1 | Pyrazole Derivatives for Treating Condit Ions Mediated by Activation of the Adeno Sine A2B or A3 Receptor | NOVARTIS AG (CH) | 2007-09-27 | — | — | US | disclosed |
| EP-1799206-A2 | PYRAZOLE DERIVATIVES FOR TREATING CONDITIONS MEDIATED BY ACTIVATION OF THE ADENOSINE A2B OR A3 RECEPTOR | Novartis AG (CH) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006015860-A2 | PYRAZOLE DERIVATIVES FOR TREATING CONDITIONS MEDIATED BY ACTIVATION OF THE ADENOSINE A2B OR A3 RECEPTOR | NOVARTIS AG (CH) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113477-A1 | Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof | ME3, ME1, MDH1 | POLB 545/4885MAPT 1964/4885HPGD 281/4885 |
| US-20070225335-A1 | Pyrazole Derivatives for Treating Condit Ions Mediated by Activation of the Adeno Sine A2B or A3 Receptor | ADORA3, ADORA2B, ADORA1 | POLB 431/4885MAPT 3851/4885HPGD 1041/4885 |
| US-20140171444-A1 | Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof | ME3, ME1, MDH1 | POLB 545/4885MAPT 1964/4885HPGD 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.